24Jul 2018

COMPARISON OF XPERTMTB/RIF AND GENOTYPE MTBDRPLUS ASSAYS IN THE DETECTION OF TUBERCULOSIS AND RIFAMPICIN RESISTANCE AMONG RETREATMENT SAMPLES IN KENYA.

  • Jomo Kenyatta University of Agriculture and Technology, College of Health Sciences.
  • Kenya Medical Research Institute, Centre for Microbiology Research, Kenya.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Tuberculosis (TB) is a major public health problem globally. The National TB program in Kenya has adopted number of new TB diagnostic tools. The present study investigated the performance of XpertMTBRIF and GenoTypeMTBDRplus in the diagnosis of Tuberculosis and rifampicin resistance among retreatment cases. Methods: A total of 561 TB retreatment sputum samples were subjected to XpertMTBRIF, MGIT culture and GenoTypeMTBDRplus assays. Thereafter, their performance in diagnosis of Mycobacterium tuberculosis and detection rifampicin resistance was compared. The sensitivity and specificity of the tests were determined and Receiver operating characteristic (ROC) analysis was performed to compare the diagnostic tools. Results: The area under the curve (AUC) for XpertMTBRIF MTB detection was 0.81 while that of LPA was 0.85. The AUC for Rifampicin resistance detection was 0.95 and 0.83 for XpertMTBRIF and GenoTypeMTBDRplus respectively. The sensitivity of XpertMTBRIF assay in the detection of MTB was 86.2% while the specificity was 74.9%. GenoTypeMTBDRplus exhibited a sensitivity of 87.8% and the specificity was 84%. On the other hand, XpertMTBRIF exhibited a high sensitivity (91.7%) and specificity (98.5%) in the detection of Rifampicin resistance. GenoTypeMTBDRplus had a sensitivity and specificity of 66.7% and 98.9% respectively. Comparison of the areas under the curve (AUC) for both tests revealed that there is no significant difference (p=0.16, p>0.05) in the detection of MTB as well as Rifampicin resistance (p=0.9, p>0.05). Conclusion: Based on the findings of this study the sensitivity and specificity of the two diagnostic tests, we recommend the use of XpertMTBRIF for surveillance since its reagents and operationalization costs are easy to implement.

  1. Bablishvili, N., Tukvadze, N., Avaliani, Z., Blumberg, H. M., & Kempker, R. R. (2015). Acomparison of the Xpert? MTB/RIF and GenoType?MTBDRplus assays in Georgia. International Journal of Tuberculosis and Lung Disease, 19(6), 676?678. https://doi.org/10.5588/ijtld.14.0867
  2. Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M. R., ? Alland, D. (2010). Evaluation of the analytical performance of the Xpert MTB/RIF assay. Journal of Clinical Microbiology, 48(7), 2495?501. https://doi.org/10.1128/JCM.00128-10
  3. Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003). The Growing Burden of Tuberculosis. Archives of Internal Medicine, 163(9), 1009. https://doi.org/10.1001/archinte.163.9.1009
  4. Gu, Y., Wang, G., Dong, W., Li, Y., Ma, Y., Shang, Y., ? Huang, H. (2015). Xpert MTB/RIF and GenoType MTBDRplus assays for the rapid diagnosis of bone and joint tuberculosis. International Journal of Infectious Diseases, 36, 27?30. https://doi.org/10.1016/j.ijid.2015.05.014
  5. Lu, D., Heeren, B., & Dunne, W. M. (2002). Comparison of the automated Mycobacteria Growth Indicator Tube system (BACTEC 960/MGIT) with L?wenstein-Jensen medium for recovery of mycobacteria from clinical specimens. American Journal of Clinical Pathology, 118(4), 542?545. https://doi.org/10.1309/65KN-2M7E-7MNN-X0TA
  6. Maynard-Smith, L., Larke, N., Peters, J. A., & Lawn, S. D. (2014). Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: A systematic review. BMC Infectious Diseases, 14(1). https://doi.org/10.1186/s12879-014-0709-7
  7. Ministry of Health, Kenya -P. T. P. survey R. (2016). Survey Report.
  8. Naidoo, P., du Toit, E., Dunbar, R., Lombard, C., Caldwell, J., Detjen, A., ? Beyers, N. (2014). A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert? MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. PLoS ONE, 9(7), e103328. https://doi.org/10.1371/journal.pone.0103328
  9. Ombura, I. P., Onyango, N., Odera, S., Mutua, F., & Nyagol, J. (2016). Prevalence of drug resistance mycobacterium tuberculosis among patients seen in coast provincial general hospital, Mombasa, Kenya. PLoS ONE, 11(10), 1?12. https://doi.org/10.1371/journal.pone.0163994
  10. Opota, O., Senn, L., Prod?hom, G., Mazza-Stalder, J., Tissot, F., Greub, G., & Jaton, K. (2016). Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country. Clinical Microbiology and Infection, 22(7), 613?619. https://doi.org/10.1016/j.cmi.2016.04.010
  11. Rahman, A., Sahrin, M., Afrin, S., Earley, K., Ahmed, S., Rahman, S. M. M., & Banu, S. (2016). Comparison of Xpert MTB/RIF assay and genotype MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in mycobacterium tuberculosis. PLoS ONE, 11(4), 1?11. https://doi.org/10.1371/journal.pone.0152694
  12. Report, G. T. (2017). TUBERCULOSIS.ISBN 978-92-4-156551-6Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Licence: CC?BY-NCSA 3.0?IGO.
  13. Rufai, S. B., Kumar, P., Singh, A., Prajapati, S., Balooni, V., & Singh, S. (2014). Comparison of xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant mycobacterium tuberculosis. Journal of Clinical Microbiology, 52(6), 1846?1852. https://doi.org/10.1128/JCM.03005-13
  14. Sekadde, M. P., Wobudeya, E., Joloba, M. L., Ssengooba, W., Kisembo, H., Bakeera-kitaka, S., & Musoke, P. (2013). Evaluation of the Xpert MTB / RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda : a cross-sectional diagnostic study. BMC Infectious Diseases, 13(1), 1. https://doi.org/10.1186/1471-2334-13-133.

[Jeremiah O, Kiiyukia C and Kiiru J. (2018); COMPARISON OF XPERTMTB/RIF AND GENOTYPE MTBDRPLUS ASSAYS IN THE DETECTION OF TUBERCULOSIS AND RIFAMPICIN RESISTANCE AMONG RETREATMENT SAMPLES IN KENYA. Int. J. of Adv. Res. 6 (Jul). 833-841] (ISSN 2320-5407). www.journalijar.com

Jeremiah Okari Ogoro
Jomo Kenyatta University of Agriculture and Technology, College of Health Sciences

DOI:

Article DOI: 10.21474/IJAR01/7431      
DOI URL: https://dx.doi.org/10.21474/IJAR01/7431

Download Full Paper

Download PDF No. of Downloads: 15 | No. of Views: 68